Abstract
Revisiting the design of phase III clinical trials of antimalarial drugs for uncomplicated Plasmodium falciparum malaria
Borrmann, S.
Peto, T.
Snow, R. W.
Gutteridge, W.
White, N. J.
PLoS Med. 2008; 5e227
Permanent descriptor
https://doi.org/10.1371/journal.pmed.0050227Steffen Borrmann and colleagues discuss appropriate endpoints and their measurement during phase III trials of new antimalarial drugs.
